ANGIOCHEM
AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.
ANGIOCHEM
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2003-01-01
Address:
Montréal, Quebec, Canada
Country:
Canada
Website Url:
http://www.angiochem.com
Total Employee:
11+
Status:
Active
Contact:
15147887801
Total Funding:
21.31 M USD
Technology used in webpage:
Euro Google Analytics Google Universal Analytics Drupal
Similar Organizations
Lucira Health
Lucira Health is a biotechnology company that offers disposable test kits to detect RNA and DNA of infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Current Advisors List
Advisor
Board_member
Founder
Investors List
Government Of Quebec
Government Of Quebec investment in Debt Financing - AngioChem
Business Development Bank of Canada
Business Development Bank of Canada investment in Series C - AngioChem
MMV Capital Partners
MMV Capital Partners investment in Venture Round - AngioChem
VIMAC Milestone Medical Fund
VIMAC Milestone Medical Fund investment in Venture Round - AngioChem
BDC Venture Capital
BDC Venture Capital investment in Venture Round - AngioChem
BDC Venture Capital
BDC Venture Capital investment in Venture Round - AngioChem
Official Site Inspections
http://www.angiochem.com Semrush global rank: 12.63 M Semrush visits lastest month: 92
Unable to get host informations!!!
More informations about "AngioChem"
ANGIOCHEM INC. | Canada Corporation Directory
ANGIOCHEM INC. is a Non-distributing corporation with 50 or fewer shareholders corporation type, which located at 1000 De La Gauchetière Street West Suite 2100 Montréal QC H3B 4W5 …See details»
Angiochem Inc. · 1000 De La Gauchetière Street West, Suite 2100 ...
ANGIOCHEM INC. is a federal corporation in Montréal, Quebec incorporated with Corporations Canada, a division of Innovation, Science and Economic Development (ISED) Canada. The …See details»
Angiochem Inc. | BDC.ca
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases. Trade uncertainty: …See details»
Angiochem 2025 Company Profile: Valuation, Funding & Investors
Angiochem General Information Description. Developer of pharmaceutical drugs designed to treat brain-related disorders. The company's drugs have the potential to treat a wide range of …See details»
Angiochem Company Profile | Management and Employees List
AngioChem was founded in 2003 and based in Quebec, Canada. Popular Searches. AngioChem Inc. Angiochem. Primary Industries. Business Services Research & Development. Contact …See details»
AngioChem - 2025 Company Profile, Funding & Competitors
Apr 8, 2025 AngioChem is a series C company based in Montreal (Canada), founded in 2003. It operates as a Develops Peptide drug conjugates for the treatment of neurological diseases. …See details»
Angiochem Company Profile - Office Locations, Competitors
Angiochem is a biotech company discovering and developing medications that are crossing the blood-brain barrier (BBB) to treat brain diseases. It focuses on peptide drug conjugates that …See details»
Angiochem: Contact Details and Business Profile - RocketReach
Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered …See details»
AngioChem - Funding, Financials, Valuation & Investors
AngioChem develops new drugs that are capable of crossing the blood-brain barrier to treat brain diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. ... How much …See details»
Angiochem - VentureRadar
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the …See details»
Angiochem Inc. | PwC Canada
On February 13, 2025, with the authorization of the inspectors of the bankruptcy of Angiochem Inc., the Trustee has filed on behalf of the Debtor a proposal under the Bankruptcy and …See details»
AngioChem - Products, Competitors, Financials, Employees, …
AngioChem's products are designed to address medical needs that are currently unmet due to the challenges posed by the blood-brain barrier. It was founded in 2003 and is based in Montreal, …See details»
AngioChem - $5.6 M Revenue | Kona Equity
AngioChem (angiochem.com) in Westmount, Quebec. AngioChem is a clinical stage biotechnology company that develops new drugs capable of crossing the blood brain barrier to …See details»
Angiochem Inc. - Osler, Hoskin & Harcourt LLP
On August 1, 2018, Angiochem Inc. announced that it had completed its Series C financing round of $7.5 million. Angiochem Inc. plans to use the financing to support the development of …See details»
Organization | Angiochem Inc
Angiochem Inc Report issue. For profit Phase 2 Phase 3. Founded: Montreal Canada (2003 ... Organization Overview. First Clinical Trial. 2007 NCT00539344. First Marketed Drug. None …See details»
AngioChem - Contacts, Employees, Board Members, Advisors
Organization. AngioChem . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Number of Board Member and Advisor …See details»
Angiochem - MassBio
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the …See details»
Angiochem Inc. - Osler, Hoskin & Harcourt S.E.N.C.R.L./s.r.l.
Angiochem Inc. est une société de biotechnologie au stade clinique de Montréal qui découvre et développe de nouveaux médicaments pour traiter diverses maladies neurologiques. Osler, …See details»
Angiochem - Overview, News & Similar companies | ZoomInfo.com
Angiochem Announces Special Protocol Assessment (SPA) with US Food and Drug Administration (FDA) MONTREAL, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Angiochem Inc. …See details»